Sonoma Pharmaceuticals (SNOA)
(Delayed Data from NSDQ)
$0.23 USD
-0.01 (-2.98%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $0.23 0.00 (-2.04%) 4:28 PM ET
2-Buy of 5 2
D Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
SNOA 0.23 -0.01(-2.98%)
Will SNOA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SNOA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SNOA
Beat the Market Like Zacks: Starbucks, Shopify, 3M in Focus
Sonoma Pharmaceuticals (SNOA) Is Attractively Priced Despite Fast-paced Momentum
SNOA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sonoma Pharmaceuticals (SNOA) Shows Fast-paced Momentum But Is Still a Bargain Stock
Other News for SNOA
Sonoma, MicroSafe announce Australian TGA approval for NanoCyn extended claims
Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
SNOA Stock Earnings: Sonoma Pharmaceuticals Misses EPS, Misses Revenue for Q1 2025